Scholar Rock (SRRK) Stock Price, News & Analysis

Company Overview

Scholar Rock, Inc. is a biopharmaceutical company focused on developing medicines that selectively target growth factors in their latent forms. The company’s approach is designed to modulate the activation of growth factors in specific tissues, with the goal of addressing diseases in which these biological pathways contribute to impaired function or abnormal tissue growth.

Scholar Rock’s lead program is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin. The company has studied apitegromab as a potential treatment for spinal muscular atrophy, a genetic neuromuscular disorder that causes progressive muscle weakness and loss of motor function. Scholar Rock has also conducted research involving its growth-factor-targeting platform in other disease areas, including oncology and muscle-related conditions.

Founded in 2012 and headquartered in Cambridge, Massachusetts, Scholar Rock conducts research and development activities primarily in the United States. The company’s programs are investigational unless and until they receive regulatory approval. Scholar Rock has been led by President and Chief Executive Officer Jay Backstrom, M.D., who joined the company after serving in senior medical and research leadership roles in the biopharmaceutical industry.

Key Stats

• Today's Range: $49.40 to $51.74
• 50-Day Range: $45.85 to $60.04
• 52-Week Range: $27.07 to $61.76
• Volume: 1.04 million shs
• Average Volume: 1.41 million shs
• Market Capitalization: $6.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $66.69
• Consensus Rating: Moderate Buy

Scholar Rock Stock Analysis - MarketRank™

Scholar Rock scored higher than 74% of companies evaluated by MarketBeat, and ranked 161st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Scholar Rock has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 4 strong buy ratings, 11 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

Scholar Rock has a consensus price target of $66.69, representing about 32.7% upside from its current price of $50.27.

Amount of Analyst Coverage

Scholar Rock has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Scholar Rock are expected to grow in the coming year, from ($3.24) to ($2.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Scholar Rock is -14.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scholar Rock is -14.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Scholar Rock has a P/B Ratio of 20.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.48% of the float of Scholar Rock has been sold short.

Short Interest Ratio / Days to Cover

Scholar Rock has a short interest ratio ("days to cover") of 15.36, which indicates bearish sentiment.

Change versus previous month

Short interest in Scholar Rock has recently decreased by 1.16%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scholar Rock does not currently pay a dividend.

Dividend Growth

Scholar Rock does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.72

News Sentiment

Scholar Rock has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Scholar Rock this week, compared to 6 articles on an average week.

Search Interest

2 people have searched for SRRK on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Scholar Rock insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $923,108.00 in company stock.

Percentage Held by Insiders

10.30% of the stock of Scholar Rock is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.08% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SRRK
• CIK: 1727196
• Web: www.scholarrock.com
• Phone: (857) 259-3860
• Fax: 866-493-4935
• Employees: 289
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Scholar Rock: $66.69
• High Price Target: $84.00
• Low Price Target: $42.00
• Potential Upside/Downside: +33.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$377.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -160.19%
• Return on Assets: -87.18%

Debt

• Debt-to-Equity Ratio: 0.77
• Current Ratio: 7.02
• Quick Ratio: 7.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.41 per share
• Price / Book: 20.67

Miscellaneous

• Outstanding Shares: 121,790,000
• Free Float: 109,241,000
• Market Cap: $6.07 billion
• Optionable: Optionable
• Beta: 0.67